Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.26 SEK -0.1% Market Closed
Market Cap: 663.5m SEK
Have any thoughts about
Orexo AB?
Write Note

Relative Value

The Relative Value of one ORX stock under the Base Case scenario is 37.36 SEK. Compared to the current market price of 19.26 SEK, Orexo AB is Undervalued by 48%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORX Relative Value
Base Case
37.36 SEK
Undervaluation 48%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
72
Median 3Y
1
Median 5Y
1.3
Industry
2.5
Forward
1.1
vs History
vs Industry
Median 3Y
-4
Median 5Y
-3.8
Industry
21.8
Forward
-5.5
vs History
vs Industry
Median 3Y
-4
Median 5Y
-3.6
Industry
16.1
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-2.9
Industry
23.8
vs History
vs Industry
7
Median 3Y
3
Median 5Y
2.9
Industry
2.1
vs History
82
vs Industry
82
Median 3Y
1.3
Median 5Y
1.5
Industry
2.7
Forward
1.7
vs History
88
vs Industry
84
Median 3Y
1.6
Median 5Y
1.8
Industry
5.2
vs History
12
vs Industry
25
Median 3Y
-6
Median 5Y
-5
Industry
13.5
Forward
49.2
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.6
Industry
16.8
Forward
-16.6
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-4.7
Industry
15.2
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.3
Industry
19.3
vs History
60
vs Industry
72
Median 3Y
1.2
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

ORX Competitors Multiples
Orexo AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Orexo AB
STO:ORX
663.5m SEK 1.1 -6.3 31.2 -20
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
SE
Orexo AB
STO:ORX
Average P/S: 382 941.9
1.1
13%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
SE
Orexo AB
STO:ORX
Average P/E: 31.6
Negative Multiple: -6.3
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 416.4
31.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 2 010.8
Negative Multiple: -20
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Discover More
Back to Top